Forensic Toxicology

, Volume 31, Issue 2, pp 263–271 | Cite as

Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine

  • Bjoern Moosmann
  • Melanie Hutter
  • Laura M. Huppertz
  • Sascha Ferlaino
  • Lisa Redlingshöfer
  • Volker AuwärterEmail author
Original Article


In 2012, online shops selling so-called research chemicals started offering pyrazolam, a new benzodiazepine that differs from phenazepam and etizolam, which have also recently appeared on the “gray market”, in that it is not marketed by pharmaceutical companies anywhere in the world. This article describes the characterization of pyrazolam (8-bromo-1-methyl-6-pyridin-2-yl-4H-[1,2,4]triazolo[4,3–a][1, 4]benzodiazepine) using gas chromatography-mass spectrometry, liquid chromatography-tandem mass spectrometry (LC–MS–MS), liquid chromatography quadrupole time-of-flight mass spectrometry (LC–Q–TOF–MS), and nuclear magnetic resonance spectroscopy. In addition, a study was carried out in which one of the authors ingested two 0.5-mg pyrazolam tablets. Serum and urine samples were then obtained to investigate the metabolism of pyrazolam and to obtain preliminary results for the elimination half-life and the detectability of a 1-mg dose in serum and urine using a highly sensitive LC–MS–MS method and immunoassays. The results showed an elimination half-life of about 17 h and no detectable metabolism. The parent compound was detected with the described LC–MS–MS method in serum for more than 50 h and in urine for approximately 6 days. Immunoassays showed cross-reactivity, but poor detection in the study samples demonstrated that consumption or administration of this presumably potent drug could go undetected unless instrumental analytical techniques are also used.


Pyrazolam Designer benzodiazepine LC–MS–MS NMR Serum Urine 


Conflict of interest

There are no financial or other relations that could lead to a conflict of interest.


  1. 1.
    UNODC (2012) World Drug Report 2012. (United Nations Publication, Sales No. E11.XI.10)Google Scholar
  2. 2.
    Lohse MJ, Müller-Oerlinghausen B (2011) Arzneiverordnungs-Report 2011. In: Schwabe U, Paffrath D (eds), Arzneiverordnungs-Report 2011. Springer, Heidelberg, pp 645–658Google Scholar
  3. 3.
    Glaeske G (2012) Medikamente–Psychotrope und andere Arzneimittel mit Missbrauchs- und Abhängigkeitspotenzial. In: Deutsche Hauptstelle für Suchtfragen (ed) Jahrbuch Sucht, Papst, Lengerich, pp 90–111Google Scholar
  4. 4.
    Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreiros N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837PubMedCrossRefGoogle Scholar
  5. 5.
    Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y (2009) Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull 57:439–441PubMedCrossRefGoogle Scholar
  6. 6.
    Kneisel S, Bisel P, Brecht V, Broecker S, Müller M, Auwärter V (2012) Identification of the cannabimimetic AM-1220 and its azepane isomer (N-methylazepan-3-yl)-3-(1-naphthoyl)indole in a research chemical and several herbal mixtures. Forensic Toxicol 30:126–134Google Scholar
  7. 7.
    Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2012) Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products. Forensic Toxicol 30:114–125CrossRefGoogle Scholar
  8. 8.
    Namera A, Nakamoto A, Saito T, Nagao M (2011) Colorimetric detection and chromatographic analyses of designer drugs in biological materials: a comprehensive review. Forensic Toxicol 29:1–24CrossRefGoogle Scholar
  9. 9.
    Zaitsu K, Katagi M, Tatsuno M, Sato T, Tsuchihashi H, Suzuki K (2011) Recently abused β-keto derivatives of 3,4-methylenedioxyphenylalkylamines: a review of their metabolisms and toxicological analysis. Forensic Toxicol 29:73–84CrossRefGoogle Scholar
  10. 10.
    Maskell PD, De Paoli G, Nitin Seetohul L, Pounder DJ (2012) Phenazepam: the drug that came in from the cold. J Forensic Leg Med 19:122–125PubMedCrossRefGoogle Scholar
  11. 11.
    (2012) EMCDDA reporting form on the new drug Pyrazolam. REITOX, Finland. Accessible via EDND database of the EMCDDAGoogle Scholar
  12. 12.
    Hester JB, Von Voigtlander P (1979) 6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity. J Med Chem 22:1390–1398PubMedCrossRefGoogle Scholar
  13. 13.
    Council of Europe (2007) Alprazolam. European Pharmacopoeia, 6th ed. Council of Europe, Strasbourg, pp 1601–1603Google Scholar
  14. 14.
    Maurer HH, Pfleger K, Weber AA (2011) Mass spectral and GC data of drugs, poisons, pesticides, pollutants and their metabolites, 4th edn. Wiley-VCH, WeinheimGoogle Scholar
  15. 15.
    Wohlfarth A, Naue J, Lutz-Bonengel S, Dresen S, Auwärter V (2012) Cocktail approach for in vivo phenotyping of 5 major cyp450 isoenzymes: development of an effective sampling, extraction, and analytical procedure and pilot study with comparative genotyping. J Clin Pharmacol 52:1200–1214PubMedCrossRefGoogle Scholar
  16. 16.
    Eberts FS Jr, Philopoulos Y, Reineke LM, Vliek RW (1981) Triazolam disposition. Clin Pharm Ther 29:81–93CrossRefGoogle Scholar
  17. 17.
    Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, Jones B (2009) In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol 67:445–454PubMedCrossRefGoogle Scholar
  18. 18.
    Kitagawa H, Esumi Y, Kurosawa S, Sekine S, Yokoshima T (1979) Metabolism of 8-chloro-6-(o-chlorophenyl)-1-methyl- 4H-s-triazolo [4,3-a] [1,4] benzodiazepine, triazolam, a new central depressant. I. Absorption, distribution and excretion in rats, dogs and monkeys. Xenobiotica 9:415–428PubMedCrossRefGoogle Scholar
  19. 19.
    Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89–96PubMedGoogle Scholar
  20. 20.
    Gorski JC, Jones DR, Hamman MA, Wrighton SA, Hall SD (1999) Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica 29:931–944PubMedCrossRefGoogle Scholar
  21. 21.
    Jenkins AJ (2007) Pharmacokinetics: drug absorption, distribution, and elimination. In: Karch SB (ed) Drug abuse handbook. CRC Press, Boca Raton, pp 177–180Google Scholar

Copyright information

© Japanese Association of Forensic Toxicology and Springer Japan 2013

Authors and Affiliations

  • Bjoern Moosmann
    • 1
    • 2
  • Melanie Hutter
    • 1
    • 2
  • Laura M. Huppertz
    • 1
  • Sascha Ferlaino
    • 3
  • Lisa Redlingshöfer
    • 1
  • Volker Auwärter
    • 1
    Email author
  1. 1.Institute of Forensic Medicine, Forensic Toxicology DepartmentUniversity Medical Center FreiburgFreiburgGermany
  2. 2.Hermann Staudinger Graduate SchoolUniversity of FreiburgFreiburgGermany
  3. 3.Institute of Pharmaceutical SciencesUniversity of FreiburgFreiburgGermany

Personalised recommendations